Buprenorphine Patch, Extended Release
Product Images NDC 69238-1204

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 69238-1204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Buprenorphine Transdermal System 1)

Chemical structure diagram of buprenorphine showing its molecular framework with rings, hydroxyl groups, nitrogen, and methyl substituents. The diagram uses standard chemical notation including bonds, atoms, and stereochemistry indicators.*

FDA Label Image

Figure E (Buprenorphine Transdermal System 10)

An instructional diagram showing a Buprenorphine extended-release transdermal patch in its packaging. The diagram labels the patch, foil backing, and foil handle, illustrating how the patch is enclosed and should be handled before application.*

FDA Label Image

Figure F (Buprenorphine Transdermal System 11)

An instructional illustration showing two hands peeling open a pouch containing a transdermal patch. This image likely demonstrates how to correctly remove a Buprenorphine extended-release transdermal patch from its packaging prior to application.*

FDA Label Image

Figure G (Buprenorphine Transdermal System 12)

An instructional illustration showing a person applying a transdermal patch on the upper chest area, demonstrating the site and method for placing a Buprenorphine extended-release patch. The image highlights proper patch placement on the skin as part of usage directions.*

FDA Label Image

Figure H (Buprenorphine Transdermal System 13)

An instructional illustration showing a person applying a Buprenorphine transdermal patch to the upper arm. The image depicts hands peeling the patch from its backing and placing it onto the skin, demonstrating the correct application site and method for this extended-release patch dosage form.*

FDA Label Image

Figure I (Buprenorphine Transdermal System 14)

An instructional line drawing showing a person applying a buprenorphine transdermal patch on the upper chest near the shoulder. The image demonstrates proper patch placement for the extended-release transdermal dosage form.*

FDA Label Image

Figure J (Buprenorphine Transdermal System 15)

An instructional illustration showing a person holding and interacting with a piece of paper or card labeled 'Disposal Unit.' The paper includes pictorial steps and instructions for disposal, depicted in four small panels, demonstrating the proper way to handle and dispose of the item safely.*

FDA Label Image

Figure K (Buprenorphine Transdermal System 16)

An instructional black-and-white illustration showing hands opening or peeling back a protective layer from a product, likely a patch. The image is labeled with the number 1 in the top left corner, indicating the first step in a usage or application guide for the Buprenorphine transdermal patch.*

FDA Label Image

Figure L (Buprenorphine Transdermal System 17)

An instructional diagram showing a hand holding a rectangular patch, likely depicting part of the application process for the Buprenorphine transdermal patch. The illustration also includes a numbered step and small pictorial instructions, suggesting step 2 in a multi-step user guide.*

FDA Label Image

Figure M (Buprenorphine Transdermal System 18)

An instructional illustration showing two hands peeling back a protective layer from a rectangular patch. The image likely depicts a step in the application process for a transdermal patch, such as Buprenorphine extended-release patch.*

FDA Label Image

Figure N (Buprenorphine Transdermal System 19)

Instructional illustration showing hands removing or applying a Buprenorphine transdermal patch from or onto a flat surface, likely part of a usage guide for the extended-release patch dosage form by Amneal Pharmaceuticals NY LLC.*

FDA Label Image

Figure 1: Cross-section (Buprenorphine Transdermal System 2)

An illustration showing the layered structure of a Buprenorphine transdermal patch. Layers include the backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and peel-off release liner, indicating components of the extended-release patch design.*

FDA Label Image

Figure O (Buprenorphine Transdermal System 20)

An instructional illustration showing a hand disposing of a patch in a container, indicating proper disposal of used Buprenorphine transdermal patches.*

FDA Label Image

Figure P (Buprenorphine Transdermal System 21)

An instructional illustration showing a hand placing a buprenorphine patch into a container or disposal unit. The image appears to demonstrate the proper disposal or handling of the transdermal patch for the medication Buprenorphine.*

FDA Label Image

5 Mcg- Pouch (Buprenorphine Transdermal System 22)

Label for Buprenorphine Transdermal System 5 mcg/hour patch by Amneal Pharmaceuticals NY LLC. The label includes storage instructions, bar code, lot and expiration date boxes, and the Amneal logo. It highlights the patch's systemic delivery of 5 mcg/hour of buprenorphine over seven days and warnings against its use in certain serious breathing problems.*

FDA Label Image

5 Mcg- Carton (Buprenorphine Transdermal System 23)

Packaging label for Buprenorphine Transdermal System 5 mcg/hour extended release transdermal patch. The label includes warnings, dosage strengths, instructional tables for date applied/removed and application site, storage instructions, and manufacturer information for Amneal Pharmaceuticals LLC. The label prominently displays the strength and dosage form on multiple panels along with regulatory information and the Controlled Substance Schedule III symbol.*

FDA Label Image

7.5 Mcg- Pouch (Buprenorphine Transdermal System 24)

Packaging label for Buprenorphine System Transdermal 7.5 mcg/hour patch by Amneal Pharmaceuticals NY LLC. The label includes usage warnings to keep the patch in unopened foil pouch until use and to keep out of reach of children. The label features storage instructions, a barcode, and areas for lot and expiration dates. It contains one 7.5 mcg/hour transdermal system patch.*

FDA Label Image

7.5 Mcg- Carton (Buprenorphine Transdermal System 25)

The packaging label for Buprenorphine Transdermal System 7.5 mcg/hour, a transdermal patch by Amneal Pharmaceuticals NY LLC. The label states each patch delivers 7.5 mcg of buprenorphine per hour for seven days. It includes dosing instructions, storage conditions, and a table to record application date, removal date, and site. The label also highlights warnings regarding respiratory risks and the requirement to provide a medication guide to patients.*

FDA Label Image

10 Mcg- Pouch (Buprenorphine Transdermal System 26)

Label for Buprenorphine Transdermal System 10 mcg/hour patch by Amneal Pharmaceuticals NY LLC. The label states the patch delivers 10 mcg of buprenorphine per hour for seven days. It includes storage instructions, warnings about use in breathing problems, and instructions to keep out of reach of children. The label features the Amneal logo and has areas for lot number and expiration date.*

FDA Label Image

10 Mcg- Carton (Buprenorphine Transdermal System 27)

Packaging label for Buprenorphine Transdermal System 10 mcg/hour patch by Amneal Pharmaceuticals LLC. The label includes dosage strength, usage instructions, a table for recording application dates and sites, storage conditions, and a barcode. The design features orange highlights and regulatory information for opioid-experienced patients only.*

FDA Label Image

15 Mcg- Pouch (Buprenorphine Transdermal System 28)

Label for Buprenorphine Transdermal System 15 mcg/hour, an extended-release transdermal patch by Amneal Pharmaceuticals NY LLC. The label includes storage instructions, a barcode, and a pink vertical panel with the product strength. It states the system delivers 15 mcg per hour over seven days and cautions against use in serious breathing problems.*

FDA Label Image

15 Mcg- Carton (Buprenorphine Transdermal System 29)

Packaging label for Buprenorphine Transdermal System 15 mcg/hour, an extended-release transdermal patch by Amneal Pharmaceuticals LLC. The label includes usage warnings, dosage information, a table for recording application dates and sites, and storage instructions. The product is intended for systemic delivery of 15 mcg buprenorphine per hour for seven days.*

FDA Label Image

Lk (Buprenorphine Transdermal System 3)

A pharmacokinetic line graph depicting buprenorphine plasma concentration (pg/mL) over time (days) for a 10 mcg/hour transdermal system worn continuously every 7 days for three cycles on 36 subjects. Concentration peaks and troughs occur roughly every 7 days, with rapid decline after patch removal on day 21, showing mean values with error bars.*

FDA Label Image

20 Mcg- Pouch (Buprenorphine Transdermal System 30)

Label for Buprenorphine Transdermal System 20 mcg/hour extended release patch by Amneal Pharmaceuticals NY LLC. The label includes usage instructions, storage conditions, warnings to keep out of reach of children, and manufacturer and distributor details. It features a green highlight for the strength '20 mcg/hour' and barcodes for product identification.*

FDA Label Image

20 Mcg- Carton (Buprenorphine Transdermal System 31)

Box packaging label for Buprenorphine Transdermal System 20 mcg/hour patch, an extended-release transdermal drug by Amneal Pharmaceuticals LLC. The label includes dosage strength, administration information, a barcode, a table for application tracking, and warnings about respiratory risks and proper use. It states systemic delivery of 20 mcg per hour for seven days and has handling/storage instructions.*

FDA Label Image

Bh (Buprenorphine Transdermal System 4)

A line graph comparing the percentage of patients improved versus the percent of reduction or improvement in pain for a placebo and Buprenorphine Transdermal System 10/20. The x-axis represents percent reduction/improvement in pain from more than 0% to 100%, while the y-axis shows the percentage of patients improved ranging from 0 to 100%. The Buprenorphine line shows consistently higher patient improvement percentages across the range compared to placebo.*

FDA Label Image

Yu (Buprenorphine Transdermal System 5)

A line graph comparing the percentage of patients improved against the percent reduction or improvement in pain for two Buprenorphine transdermal systems at 5 mcg/hr and 20 mcg/hr dosages. The graph shows patient response rates decreasing as pain reduction percentage increases, with the 20 mcg/hr system showing higher patient improvement rates than the 5 mcg/hr system.*

FDA Label Image

Figure A (Buprenorphine Transdermal System 6)

An instructional illustration depicting four possible placement sites for the Buprenorphine transdermal patch on the human body, including the upper arm, upper chest, upper back, and side of the chest below the armpit.*

FDA Label Image

Figure B (Buprenorphine Transdermal System 7)

An anatomical illustration showing the upper back and shoulder area of a person with two rectangular patches applied side-by-side on the upper left shoulder. The image depicts the proper application site for Buprenorphine transdermal extended-release patches.*

FDA Label Image

Figure C (Buprenorphine Transdermal System 8)

An instructional line drawing showing a person applying a transdermal patch to the upper left chest area, illustrating correct placement for a Buprenorphine extended release patch.*

FDA Label Image

Figure D (Buprenorphine Transdermal System 9)

An instructional black-and-white illustration showing two hands using scissors to cut a square adhesive patch, likely representing a transdermal patch associated with Buprenorphine extended-release. The image likely demonstrates how to cut the patch before application.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.